Calcium and oxytocin combo Better for inducing labor in term women with premature rupture of membranes: Study

A study published in the American Journal of Obstetrics & Gynecology MFM suggests that a calcium and oxytocin combo is better for inducing labor in term women with premature membrane rupture.

Intravenous calcium administration has shown promise in enhancing uterine contractions and reducing blood loss during cesarean delivery, but this regimen has not been compared in vaginal labor induction. This study aimed to determine the efficacy of oxytocin combined with calcium vs oxytocin alone for inducing labor in women with term premature rupture of membranes. This single-blind, randomized controlled trial was conducted between October 2022 and May 2023 at a tertiary university hospital. Patients diagnosed with premature rupture of membranes were randomly allocated into 2 groups. The intervention group received a bolus of 10 mL of calcium gluconate followed by a continuous infusion of oxytocin via a pump (n=210), whereas the control group received only oxytocin infusion (n=218). The primary outcome was successful vaginal deliveries within 24 hours after labor induction. The secondary outcomes included the interval from labor induction to delivery, vaginal delivery blood loss, and maternal and neonatal complications. RESULTS: Baseline characteristics, including maternal age, body mass index, and Bishop score before labor induction, were comparable between the groups. The rate of vaginal delivery within 24 hours after labor induction was statistically higher in the intervention group (79.52% vs 70.64%; P=.04). The participants in the intervention group experienced a shortened interval between labor induction and delivery (10.48 vs 11.25 hours; P=.037) and demonstrated a higher success rate in labor induction assessed by the onset of the active phase (93.80% vs 87.61%; P=.04) without increasing the cesarean delivery rate. Reduced hemorrhage was observed in the intervention group (242.5 vs 255.0 mL; P=.0015), and the maternal and neonatal outcomes were comparable between the groups. The coadministration of calcium and oxytocin in labor induction among pregnancies with premature rupture of membranes was more efficient and safer than the administration of oxytocin alone. Our research suggests that the combination therapy of calcium and oxytocin may offer significant advantages during the process of labor induction and result in better outcomes.

Reference:

Ruixiang Cai, Lingyan Chen, Yunguang Xing, Yuguo Deng, Juan Li, Fangfang Guo, Li Liu, Cuihua Xie, Jinying Yang. Oxytocin with calcium vs oxytocin for induction of labor in women with term premature rupture of membranes: a randomized controlled trial. American Journal of Obstetrics & Gynecology MFM, Volume 6, Issue 11, 2024, 101502, ISSN 2589-9333,

https://doi.org/10.1016/j.ajogmf.2024.101502.

(https://www.sciencedirect.com/science/article/pii/S2589933324002283)

Keywords:

Calcium, oxytocin, combo, Better, inducing, labor, term, women, premature, rupture, membranes, study, American Journal of Obstetrics & Gynecology MFM, Ruixiang Cai, Lingyan Chen, Yunguang Xing, Yuguo Deng, Juan Li, Fangfang Guo, Li Liu, Cuihua Xie, Jinying Yang

Powered by WPeMatico

Chronic Endometritis associated with Caesarean Scar Diverticulum leading to prolonged menstruation and anemia: Study

Chronic Endometritis associated with Caesarean Scar Diverticulum leading to prolonged menstruation and anemia suggests a study published in the Journal of Reproductive Immunology.

A study was done to investigate the risk factors for Caesarean Scar Diverticulum (CSD) with Chronic Endometritis (CE) and the correlation between CE and clinical symptoms of CSD. The frequency of CE in 44 patients with CSD who underwent surgical treatment and 20 control women who underwent total hysterectomy was assessed and the clinical symptoms in the presence and absence of CE were compared. In accordance with the presence of one or more CD138-positive plasma cells per high-power field, CE was classified as mild or severe group. Results: According to multivariate analysis, the presence of mild CE (OR 8.963, 95 % CI 2.177–36.907, p = 0.002) or severe CE (OR 21.773, 95 % CI 2.285–207.419, p = 0.007) was significantly associated with CSD. Mild CE (OR 12.390, 95 % CI 1.158–132.511, p = 0.037) or severe CE (OR 22.463, 95 % CI 1.657–304.541, P = 0.019) or depth of diverticulum (OR 1.294, 95 % CI 1.003–1.668, p = 0.047) was associated with prolonged menstruation in patients with CSD. The degree of CE in patients with CSD was positively correlated with the days of prolonged menstruation (r = 0.552, p < 0.001) and negatively correlated with haemoglobin level (r = −0.408, p = 0.038). CE was associated with CSD and its clinical symptoms, including prolonged menstruation and decreased haemoglobin. The severity of clinical symptoms of CSD is associated with endometrial inflammation.

Reference:

Junchao Zhang, Jinfa Huang, Zexian Xu, Qian Yang, Lingling Zeng, Lei Zhou, Kaixian Deng,

The correlation between chronic endometritis and Caesarean scar diverticulum. Journal of Reproductive Immunology, Volume 166, 2024, 104324, ISSN 0165-0378,

https://doi.org/10.1016/j.jri.2024.104324.

(https://www.sciencedirect.com/science/article/pii/S0165037824001335)

Keywords:

Chronic, Endometritis, associated, Caesarean, Scar, Diverticulum, leading, prolonged, menstruation, anemia, study , Journal of Reproductive Immunology, Junchao Zhang, Jinfa Huang, Zexian Xu, Qian Yang, Lingling Zeng, Lei Zhou, Kaixian Deng

Powered by WPeMatico

Ibuprofen injection exhibits kidney safety with cost benefits over ketorolac: Study

Cumberland Pharmaceuticals announced the publication of a new study demonstrating the safety advantages and cost-saving potential of its Caldolor (ibuprofen) injection when compared to ketorolac in both adult and pediatric patients. The research was published in Frontiers in Pain Research presented real-world outcomes that show Caldolor significantly reduces adverse drug reactions (ADRs) and healthcare resource utilization (HCRU) offered a promising alternative to ketorolac for pain management.

The retrospective analysis of over 17 million patient records compared the outcomes of patients who received either Caldolor or ketorolac. A total of 31,046 adult patients who received Caldolor were matched against 1,24,184 adults who were administered ketorolac. An additional 5,579 pediatric patients were analyzed in separate comparisons. The primary endpoints were the rates of adverse drug reactions and the subsequent healthcare resource utilization which included emergency department visits, inpatient admissions, outpatient visits and medical procedures.

The key findings of the study revealed that in adults, Caldolor was associated with a 45% reduction in renal dysfunction and a 78% decrease in hematuria when compared to ketorolac. These results were statistically significant (p<0.001). Further, fewer gastrointestinal complications and reduced occurrences of common side effects such as headaches, nausea, and abdominal pain were observed in patients using Caldolor. For pediatric patients, Caldolor demonstrated a 51-65% lower rate of ADRs, including a decrease in headaches and nausea, with results supporting clinical significance.

In addition, Caldolor was also linked to a reduction in healthcare costs. The study found that adults and children treated with Caldolor experienced fewer emergency room visits, reduced outpatient consultations and shorter hospital stays when compared to the ones treated with ketorolac. This suggests that Caldolor could contribute to lower overall healthcare expenditures by minimizing complications and the need for additional treatments.

The study confirms the potential of Caldolor to improve patient outcomes while also offering significant cost savings for healthcare systems, added A.J. Kazimi, the CEO of Cumberland Pharmaceuticals. Overall, Caldolor was the first FDA-approved intravenous therapy for fever and is indicated for the treatment of mild to moderate pain, as well as moderate to severe pain in combination with opioid analgesics. It is also used to reduce fever in both adults and pediatric patients.

Source:

Cumberland Pharmaceuticals Inc. (2024, November 5). New Study Compares Caldolor® (ibuprofen injection) to ketorolac. PR Newswire. https://www.prnewswire.com/news-releases/new-study-compares-caldolor-ibuprofen-injection-to-ketorolac-302296908.html

Powered by WPeMatico

Multiple penicillin courses may modestly lower risk for Parkinson disease, reveals research

Researchers have reported that early exposure to a few antimicrobials, like penicillins and antifungals, could impact the risk for Parkinson’s disease (PD) in later life. A new study of the Clinical Practice Research Datalink (CPRD) data reported an association where people exposed to higher courses of penicillins had reduced PD risk but those who had multiple antifungal prescriptions had a minor increase in PD risk. The study was conducted by Gian Pal and colleagues and was published in the journal Parkinsonism and Related Disorders.

Parkinson’s disease is a complex neurodegenerative disorder influenced by genetic and environmental factors, but its relationship with prior antimicrobial exposure remains unclear. This study, conducted using a UK-representative population, analyzed whether exposure to different antimicrobials affected the likelihood of developing PD.

The nested case-control study design was carried out with a sample sourced from CPRD. For this study, researchers analyzed data sourced from CPRD for 12,557 cases of PD and controls matched to them, 80,804 controls. Controls and PD cases were matched one to one based on age, sex, and year of diagnosis, the index date. It reviewed prescribed courses of antimicrobials up to 1–5, 6–10, and 11–15 years before diagnosis. Logistic regression models using generalized estimating equations were applied in order to compute ORs and consider false discovery.

  • Those exposed to five or more courses of penicillin 1-5 years before the index date showed a 15% reduction in the odds of developing PD (OR 0.85; 95% CI 0.76–0.95, p = 0.043).

  • A comparable hazard was observed 6–10 years earlier: those who had the same regimen of penicillin had a 16% hazard reduction for PD compared with matched controls (OR 0.84; 95% CI 0.73–0.95, p = 0.059).

  • The association persisted 11–15 years before diagnosis but was not significant (OR 0.87; 95% CI 0.74–1.02, p = 0.291).

  • A small, non-significant reduction in the risk of PD was found to be associated with macrolide treatment courses taken 1–5 years prior to diagnosis (ORs between 0.89–0.91; 95% CI 0.79–0.99, adjusted p = 0.140–0.167).

  • This cohort had an increased risk of PD by 16% (OR 1.16; 95% CI 1.06–1.27, p = 0.020).

Overall, this large analysis speaks to a more subtle relationship between antimicrobial exposure and the risk of PD. Specifically, penicillin exposure may convey slightly lower risk for disease, whereas antifungal exposure slightly increases the risk. Such studies highlight the fact that long-term effects of antimicrobial exposure on neurodegenerative diseases should be considered.

Reference:

Pal, G., Bennett, L., Roy, J., Nyandege, A., Mouradian, M. M., Gerhard, T., & Horton, D. B. (2024). Effects of antimicrobial exposure on the risk of Parkinson’s disease. Parkinsonism & Related Disorders, 127(107081), 107081. https://doi.org/10.1016/j.parkreldis.2024.107081

Powered by WPeMatico

Image-guided thermal ablation effective treatment option for patients with papillary thyroid cancer patients: JAMA

Image-guided thermal ablation effective treatment option for patients with papillary thyroid cancer patients suggests a new study published in the JAMA.

Image-guided thermal ablation has been administered for patients with T1N0M0 papillary thyroid carcinoma (PTC) who elect to not undergo surgery or receive active surveillance. Considering the indolent nature of PTC, long-term outcomes of ablation are needed. A study was done to investigate l0-year outcomes of thermal ablation in treating T1N0M0 PTC. This multicenter study was conducted at 4 university-affiliated hospitals in China and included 179 consecutive patients with T1N0M0 PTC (median [IQR] volume, 88.0 [163.2] mm3) who underwent thermal ablation between June 2010 and March 2014. Patients who were ineligible to undergo surgery or elected not to were included, and patients had PTC tumors that were smaller than 20 mm as confirmed by biopsy; no clinical or imaging evidence of extrathyroidal extension, lymph node metastasis (LNM), or distant metastasis; and no history of neck irradiation. The primary outcomes were disease progression (LNM, newly developed tumors, persistent tumors, and distant metastasis) and disease-free survival (DFS). Secondary outcomes were technical success, volume reduction rate, tumor disappearance, complications, and delayed surgery. DFS was calculated using a Kaplan-Meier analysis. Results Among the 179 patients, the mean (SD) age was 45.8 (12.7) years, and 118 (65.9%) were female. During a mean (SD) follow-up period of 120.8 (10.8) months, disease progression was found in 11 of 179 patients (6.1%), including LNM in 4 patients (2.2%), newly developed tumors in 6 patients (3.3%), and persistent tumor in 1 patient (0.6%). The 10-year DFS was 93.9%. The technical success, median volume reduction rate, and tumor disappearance rate was 100%, 100%, and 97.2%, respectively. The magnitude of the disease progression (6.1% vs 7.1%; difference, 1.0%; 95% CI, −6.5% to 25.6%) and DFS (93.9% vs 92.9%; difference, 1.0%, 95% CI, −6.5% to 25.6%) between patients with T1a and T1b tumors was small. The difference in the rate of tumor disappearance between T1a and T1b tumors was large (99.4% vs 71.4%; difference, 28.0%; 95% CI, 10.9%-54.0%). One patient experienced transient voice hoarseness (0.6%). Because of anxiety, 1 patient underwent delayed surgery (0.6%). The results of this 10-year multicenter cohort study suggest that thermal ablation is an effective and safe alternative for patients with T1N0M0 PTC who do not undergo surgery or receive active surveillance. For safe and effective treatment, accurate radiologic evaluation, an understanding of ablation techniques, and experienced physicians are recommended.

Reference:

Yan L, Li Y, Li X, et al. Thermal Ablation for Papillary Thyroid Carcinoma. JAMA Otolaryngol Head Neck Surg. Published online November 07, 2024. doi:10.1001/jamaoto.2024.3229

Keywords:

Image-guided, thermal, ablation, effective, treatment, option, patients, papillary, thyroid, cancer, patients, JAMA , Yan L, Li Y, Li X

Powered by WPeMatico

Risk of ovarian cance very low among older women with stable adnexal masses on ultrasound, finds study

The detection of adnexal masses in older patients often raises concerns about ovarian cancer, which poses a common clinical challenge for gynecologists. While surgical evaluation is the only way to immediately rule out cancer, subjecting all patients to surgery would cause excessive harm because the vast majority of these masses are benign. Recent study aimed to assess the ovarian cancer risk among older patients with stable adnexal masses on ultrasound. It was a retrospective cohort study conducted on patients aged 50 years and older with an adnexal mass of less than 10 cm on ultrasound between 2016 and 2020 in a large community-based health system. The masses were considered stable if they did not exhibit an increase of more than 1 cm in the greatest dimension or a change in standardized reported ultrasound characteristics. The study included 4061 patients with stable masses, with an average age of 61 years and an initial mass size of 3.8 cm. Among these patients, 11 cancers were detected, resulting in an absolute risk of 0.27%. The study found that ovarian cancer risk declined with longer duration of stability, with no cancer cases observed after 52 weeks of stability. The risk of ovarian cancer was 0.73 per 1000 person-years at 6 to 12 weeks of stability, 0.63 at 13 to 24 weeks, 0.44 at 25 to 52 weeks, and 0.00 at over 52 weeks. The study suggested that ongoing ultrasound imaging would be needed for 369 patients at 6 to 12 weeks of stability, 410 patients at 13 to 24 weeks, 583 patients at 25 to 52 weeks, and over 1142 patients with stable masses at 53 to 104 weeks to detect one case of ovarian cancer. The authors concluded that the risk of ovarian cancer was very low among older women with stable masses on ultrasound. They recommended that the benefit of ultrasound monitoring beyond 12 months is minimal and may be outweighed by potential risks of repeated imaging.

Discussion

The study found that among patients aged 50 years and older with stable adnexal masses on ultrasound, the risk of ovarian cancer was low and declined with longer demonstrated stability. The researchers suggested that ultrasound monitoring of stable masses beyond 12 months is of minimal benefit and might be associated with potential risks of repeated imaging. These findings indicate that the duration of ultrasound monitoring for stable masses should be limited, considering the minimal benefit and potential risks associated with prolonged surveillance.

Conclusion

In conclusion, the study provides important insights into the ovarian cancer risk among older patients with stable adnexal masses and suggests that prolonged ultrasound monitoring may not be necessary for patients with stable masses. The researchers highlight the importance of considering the potential risks of repeated imaging when determining the optimal duration of ultrasound monitoring for stable adnexal masses.

Key Points

1. The study aimed to assess the ovarian cancer risk among older patients with stable adnexal masses on ultrasound. It was a retrospective cohort study conducted on patients aged 50 years and older with an adnexal mass of less than 10 cm on ultrasound between 2016 and 2020 in a large community-based health system. The masses were considered stable if they did not exhibit an increase of more than 1 cm in the greatest dimension or a change in standardized reported ultrasound characteristics.

2. The study included 4061 patients with stable masses, with an average age of 61 years and an initial mass size of 3.8 cm. Among these patients, 11 cancers were detected, resulting in an absolute risk of 0.27%. The study found that ovarian cancer risk declined with longer duration of stability, with no cancer cases observed after 52 weeks of stability. The risk of ovarian cancer was 0.73 per 1000 person-years at 6 to 12 weeks of stability, 0.63 at 13 to 24 weeks, 0.44 at 25 to 52 weeks, and 0.00 at over 52 weeks.

3. The study suggested that ongoing ultrasound imaging would be needed for 369 patients at 6 to 12 weeks of stability, 410 patients at 13 to 24 weeks, 583 patients at 25 to 52 weeks, and over 1142 patients with stable masses at 53 to 104 weeks to detect one case of ovarian cancer.

4. The authors concluded that the risk of ovarian cancer was very low among older women with stable masses on ultrasound. They recommended that the benefit of ultrasound monitoring beyond 12 months is minimal and may be outweighed by potential risks of repeated imaging.

5. The study found that among patients aged 50 years and older with stable adnexal masses on ultrasound, the risk of ovarian cancer was low and declined with longer demonstrated stability. The researchers suggested that ultrasound monitoring of stable masses beyond 12 months is of minimal benefit and might be associated with potential risks of repeated imaging.

6. In conclusion, the study provides important insights into the ovarian cancer risk among older patients with stable adnexal masses and suggests that prolonged ultrasound monitoring may not be necessary for patients with stable masses. The researchers highlight the importance of considering the potential risks of repeated imaging when determining the optimal duration of ultrasound monitoring for stable adnexal masses.

Reference –

Suh-Burgmann EJ, Hung YY, Schmittdiel JA. Ovarian cancer risk among older patients with stable adnexal masses. Am J Obstet Gynecol 2024;231:440.e1-7.

Powered by WPeMatico

Novel Pulmonary Valve Aims to Reduce Invasive Surgeries for Kids, finds study

One of the longstanding challenges of pediatric pulmonary valve replacement is size and the ability to accommodate growth. Young children tend to quickly outgrow fixed size valves-leading to the need for multiple invasive surgeries throughout childhood.

Now, an investigational clinical trial at Children’s Hospital Los Angeles is testing a potential solution to this problem: a novel pulmonary valve that can be size-adjusted as a child grows.

The investigational device, called the Autus Size-Adjustable Valve, is designed to be balloon-expanded-via minimally invasive catheterization procedures-as a child grows. Last year, Children’s Hospital Los Angeles became the first center on the West Coast to offer this trial, which has now expanded to 10 sites around the country.

“Currently, pediatric valvular lesions are essentially a lifelong disease,” says Luke Wiggins, MD, a congenital cardiothoracic surgeon in the Heart Institute at CHLA and the site principal investigator for the study, which also involves Darren Berman, MD. “This new technology has the potential to revolutionize the way we approach and manage these patients.”

How the valve works

The Autus Valve, which is made by Autus Valve Technologies Inc., is a fully synthetic pulmonary valve that is surgically implanted in pediatric patients. Its design mimics the geometry of the human venous valve and features two leaflets.

Because the implant diameter is customizable, surgeons can implant the valve at the size appropriate for the child. The valve is designed to function across a wide range of diameters-from 12.7 to 22 millimeters.

That’s important because while some current pulmonary valves can be balloon-dilated in a catheterization lab to open stenotic leaflets as a child grows, this can often cause the valve to leak.

“One of the unique aspects of the Autus Valve is its two-leaflet design,” Dr. Wiggins explains. “That helps accentuate coaptation of the leaflets. So, when the valve is later balloon-dilated in the Cath lab, it can maintain its competency as a one-way valve.”

Children’s Hospital Los Angeles has been part of the study since its early feasibility phase. The valve is now being studied in a Food and Drug Administration pivotal trial.

The prospective, single-arm, multicenter study plans to enroll 50 patients, ages 18 months to 16 years, who require surgical pulmonary valve replacement. CHLA has so far implanted the device in three patients.

The next frontier

Although the Autus Valve aims to address the major issues of size and growth accommodation in pediatric pulmonary valve replacement, additional challenges remain.

“There is still a lot of opportunity for improvement in pulmonary valve prostheses,” Dr. Wiggins says. “For example, many existing prosthetic heart valves require anti-coagulation, which can cause side effects in children. And many of the biologic valves in use today break down quickly because of kids’ heightened immune responses.

“I see improving these pulmonary valves as the next frontier for our field,” he adds. “This trial is an exciting step toward that future, but there is more ground to cover.”

Dr. Wiggins notes that these trials are only possible because of the multidisciplinary care at the Heart Institute-the largest heart program for children in the Western United States.

“Although the surgical team places the valve, we work very closely with our pediatric cardiologists, our echocardiography and imaging specialists, and our interventional congenital cardiologists in the Catheterization Lab,” he says. “It’s that seamless teamwork that allows us to optimize care for these patients.”

Powered by WPeMatico

UP DGME Releases Schedule For Round 1 NEET PG Counselling 2024

Uttar Pradesh: The Directorate General of Medical Education (UP DGME) released the Round 1 NEET PG 2024 counselling schedule for PG medical admissions in the state this year.

All the concerned candidates seeking to appear in the state’s NEET PG counselling are advised to take note of the information released by the UPDGME as follows:

The time table of online NEET PG counseling for the first round for admission to postgraduate courses (MD/MS/Diploma and DNB) in Government/Autonomous/private medical colleges/institutes/ universities/hospitals under medical Health is as follows:-

S.No

Description

Dates

Total Days

Date of Online Choice
Filling

18th November
2024 (From 5:00 PM) to 25th November 2024 (Till 11:00 AM)

07
days

Date
of Declaration of result of seat allotment

27th November
2024

01
days

Date
for downloading allotment letters and admission process

28th November to 30th November 2024

and
02nd December to 04th December 2024

06
days

• Only candidates registered under UP NEET PG- 2024 can participate in the counseling process.

• Only those registered candidates who have deposited the registration fee and security amount will be eligible for choice filling.

• Candidates should assess their eligibility themselves as per the provisions contained in the Government Order No. 1/687326/2024 dated 09 July 2024 regarding UP NEET PG 2024 policy and the brochure of UP NEET PG-2024.

MCC had earlier released the counselling schedule for states. As per the schedule released by MCC, the state counselling authorities will begin the counselling on November 18 2024 after the sharing of joined cnaiddtaes date by the MCC on 28th to 29th November.

Rest of the state counselling schedule is as follows:

NEET PG State Counselling Schedule

S.No.

Schedule for Admission

State Counselling

All India Quota/

Deemed &Central Universities

Sharing of

Joined candidates

Data by MCC

Sharing of Joined candidates Data by state DMEs/ State Counselling Authorities*

1

Ist Round of Counselling

20th Sept., 2024 to 20th Nov., 2024

28th Nov., 2024 to 29th Nov., 2024

18th Nov., 2024 to 27th Nov., 2024

5th Dec., 2024 to 6th Dec., 2024

2

Last date of Joining

27th Nov., 2024

_

4th Dec., 2024

_

3

2nd round of Counselling

4th Dec., 2024 to 12th Dec., 2024

21st Dec., 2024. to 22nd Dec., 2024

12th Dec., 2024 to 23rd Dec., 2024

29th Dec., 2024 to 31st Dec., 2024

4

Last date of joining

20th Dec., 2024

_

28th Dec., 2024

_

5

Round-3

26th Dec., 2024 to 1st Jan., 2025

14th Jan., 2025 to 15th Jan., 2025

7th Jan., 2025 to 13th Jan, 2025

19th Jan., 2025 to 20th Jan., 2025

6

Last date of joining

13th Jan., 2025

_

18th Jan., 2025

_

Stray Vacancy

18th Jan., 2025 to 24th Jan., 2025

31st Jan., 2025

25th Jan., 2025 to 30th Jan., 2025

_

Last date of joining

30th Jan., 2025

5th Feb., 2025

Commencement of Academic Session for PG Courses

20th December, 2024

To view the official Notice, Click here :  https://medicaldialogues.in/pdf_upload/up-neet-pg-time-schedule-for-md-ms-dimploma-dnb-260096.pdf

Powered by WPeMatico

Indira Gandhi ESI Hospital Delhi Vacancies: Walk In Interview For SR, Super Specialist Post, All Details Here

New Delhi: The Indira Gandhi Employees State Insurance Hospital (IG ESI Hospital Jhilmil) has announced vacancies for the Senior Resident, Super Specialist posts in different departments in this medical institute.

ESI is a statutory body constituted under an Act of Parliament (ESI Act, 1948) and works under the administrative control of the Ministry of Labour and Employment, Government of India.

ESIC Vacancy Details:-

Total no of Vacancies: 31

Senior Resident:- 25

The Vacancies are in the Departments of – Orthopedics, Ophthalmologist, Dermatology, Gynaecology, Pulmonologist, Psychiatry, Anesthesia, Surgery, ENT, and General Medicine.

Super Specialist:- 06

The Vacancies are in the Departments of Cardiology, Endocrinology, Gastroenterology, Nephrology, Neurology, and Urology.

The date of walk In Interview is 11th and 12th November 2024.

Venue and Reporting Time: The office of the Medical Superintendent, IG ESI Hospital, Jhilmil, New Delhi- 110095 At 9.00 AM.

For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link:
https://medicaljob.in/jobs.php?post_type=&job_tags=ESIC+DElhi&location=&job_sector=all

What are the Instructions for Eligible Candidates:-

Applicants are advised to reach the office of the Medical Superintendent, IG ESI Hospital, Delhi on the date of walk-ininterview i.e. on 11.11.2024 and 12.11.2024 at 9.00 A.M. as per scheduled interview mentioned in the advertisement along with original documents and one set of photocopies (self-attested) aslisted on the application form. No candidate will be entertained after 10.30 A.M.

The candidates must bring original documents for verification at 9.00 AM Sharp on the date of interview.

The candidates are advised to bring their all Original Certificates with one set of self-attested photocopies of the following documents during verification: –

1. Identity proof [PAN Card, Passport, Driving License, Voter Card, Aadhar Card etc.]

2. Address Proof [Ration Card, Passport, Driving License, Aadhar Card etc.]

3. Certificate showing date of birth [10th certificate/Birth certificate]

4. Two recent passport size photographs

5. Photocopies of Aadhar/PAN Card and Bank Passbook [At the time of joining for only selected candidates]

6. Class 10th/12th mark sheets and certificates 7. MBBS, MD/MS/DNB/DM and Experience certificates whichever is applicable as per NMC guidelines.

8. Registration with Medical Council of India/State Medical Council [For Medical Candidates]

9. Internship completion certificate.

10. Reservation category certificate [OBC/SC/ST/PH/EWS] in the format prescribed by Govt. of India.

11. NOC certificate from present employer if applicable

12. Experience certificate if applicable.

13. Income and Asset certificate from issuing Authority as per DOPT letter no. 36039/1/2019. Esst. (Res) dated 31st January 2019 must be submitted for the reservation for EWS Category.

Also Read:Applications Open: 77 JR Post In Various Departments At AIIMS Delhi, Check Details Here

Powered by WPeMatico

High-speed 3D bioprinter can fabricate structures that closely mimic diverse tissues in human body

Biomedical engineers from the University of Melbourne have invented a 3D printing system, or bioprinter, capable of fabricating structures that closely mimic the diverse tissues in the human body, from soft brain tissue to harder materials like cartilage and bone.

Powered by WPeMatico